---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069254"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:28:10.258203+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ProKidney Q1 net loss $38M; cash $328.5M; REGEN-007 data due Q2 2025

## Summary
- Net loss before noncontrolling interest was $38.0M for Q1 2025 vs $35.3M in Q1 2024.
- Cash, cash equivalents and marketable securities totaled $328.5M as of March 31, 2025, funding operations into mid-2027.
- Full data from Group 1 of Phase 2 REGEN-007 study expected in Q2 2025 (approx. 20 patients, ~18 months follow-up).
- FDA confirmed accelerated approval pathway for rilparencel in Q4 2024; details expected mid-2025 after Type B meeting.
- R&D expenses flat at $27.3M; G&A increased to $14.4M from $12.8M in prior-year period.

## SEC filing metadata
- accession: 0000950170-25-069254
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017025069254/0000950170-25-069254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017025069254/prok-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069254
- JSON: https://secwatch.observer/filing/0000950170-25-069254.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069254.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.